MIMEDX GROUP, INC. financial statements

Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data MIMEDX GROUP, INC. files with the SEC in its annual reports.

In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.

Income statement

	FY2016	FY2018	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	245	321	359	299	248	242	268	321	349	419
Cost of revenue	30.9	35.2	36.4	43.1	39.3	39.6	48.3	54.6	60.1	73
Gross profit	191	286	323	256	209	202	220	267	289	346
Research and development	14.3	17.9	15.8	11.1	11.7	9.93	12.7	12.7	12.3	15.1
Selling, general and administrative	173	220	259	198	181	195	209	211	225	266
Selling and marketing							151	162	176	210
General and administrative							57.4	49.3	49.5	56.5
Operating income	0.88	46.2	-3.92	-21.2	-45.4	-7.05	-14.7	37.1	58.9	63.9
Interest expense	0.34						5.05	6.58	3.94	1.78
Interest income							0.03	0.12	2.93	4.72
Other non-operating income	-0.34	0	0	0.28	-0	-0.02	-0	-0.03	-0.57	-0.56
Pre-tax income	0.55	45.1	-3.4	-25.6	-61.5	-12.1	-19.7	30.6	57.3	66.3
Income tax	0.16	-19.6	26.6	-0.01	-12.3	0.25	0.21	-36.8	15.3	17.7
Income from continuing operations						-12.3	-20	67.4	42	48.6
Net income	0.39	64.7	-30	-25.6	-49.3	-10.3	-30.2	58.2	42.4	48.6
EBITDA	4.22	50.3	1.96	-14.6	-39.6	-2.69	-11.4	40.5	64.9	78.8
EPS, basic	0.00	0.61	-0.28	-0.24	-0.77	-0.15	-0.33	0.40	0.29	0.33
EPS, diluted	0.00	0.56	-0.28	-0.24	-0.77	-0.15	-0.33	0.37	0.28	0.32
Shares, basic (weighted)	106	106	106	107	108	110	113	116	147	148
Shares, diluted (weighted)	113	116	106	107	108	110	113	146	149	150

Balance sheet

	FY2016	FY2018	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Cash and equivalents	30.3	27.5	45.1	69.1	95.8	87.1	66	82	104	166
Short-term investments	0
Receivables	1.93		0	32.3	35.4	40.4	43.1	53.9	55.8	75.7
Inventory	15.9	9.47	16	9.1	10.4	11.4	13.2	21	23.8	25.3
Other current assets	9.52	9.02	5.82	6.06	3.37	2.81	3.34	1.75	7.84	10.3
Total current assets	59.5	48.7	74	123	161	149	134	164	192	277
Property, plant and equipment	14	14.1	17.4	12.3	11.4	9.17	7.86	6.97	5.94	4.71
Lease right-of-use assets			0	3.4	3.62	4.7	3.4	2.13	5.61	4.34
Goodwill	20.2	20	20	20	20	19.4	19.4	19.4	19.4	19.4
Intangible assets	23.3	10	9.61	7.78	6	5.38	5.85	5.26	11.6	14.2
Other non-current assets	0.35	2.87	1.79	0.44	0.38	0.19	0.15	0.21	6.71	7.27
Total assets	117	121	123	167	202	188	171	239	264	343
Accounts payable	11.4		14.9	8.71	8.77	7.39	8.45	9.05	7.41	14.5
Accrued liabilities	19.2	15.8	31.8	32.2	30.5	9.81	10.9	9.36	9.01	11.4
Deferred revenue					0.55	0.56
Short-term debt			0	3.75	0			1	1	1.5
Total current liabilities	60.8	45.8	71.5	67.3	59.2	42.4	43.6	46	45.6	64.3
Long-term debt			0	61.9	47.7	48.1	48.6	48.1	17.8	16.5
Lease liabilities				2.92	2.96	3.81	2.38	0.89	4.71	3.25
Other non-current liabilities	0.88	1.65	1.64	3.54	3.76	4.87	4.77	2.22	7.38	5.37
Total liabilities	69.2	47.5	73.2	133	111	95.4	96.9	96.3	70.8	86.1
Total debt			0	73.1	50	50	50	50	19	18
Paid-in capital	161	165	165	147	159	166	174	276	284	299
Retained earnings	-111	-46.6	-76.6	-102	-151	-162	-192	-134	-91.3	-42.7
Treasury stock	-2.22	-44.4	-38.6	-10.8	-7.45	-4.02	0			0
Shareholders' equity	48.1	73.8	49.7	34.4	-0.15	0.08	-18	143	193	257
Total equity	48.1	73.8	49.7	34.4	-0.15	0.08	-18	143	193	257
Total liabilities and equity	117	121	123	167	202	188	171	239	264	343
Shares outstanding	110	109	109	111	111	112	114	146	147	148

Cash flow statement

	FY2016	FY2018	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Net income	0.39	64.7	-30	-25.6	-49.3	-10.3	-30.2	58.2	42.4	48.6
Depreciation and amortization	3.33	4.09	5.88	6.55	5.78	4.36	3.35	3.43	6.04	14.9
Stock-based compensation	17.7	21.2	14.8	12.1	15.4	14.2	11.3	17	16.9	16.4
Deferred income tax	-5.38	-26.7	25.5	0	0	0	0	-40.8	12.5	8.71
Change in receivables	0.07	-0.48	0	-10.9	-3.1	-10.6	-5.94	-12.2	-2.55	-26.4
Change in inventory	-0.9	2.75	-6.52	6.88	-1.26	-1.41	-1.79	-7.84	-2.36	-1.53
Change in payables	-3.48	-1.32	6.59	-6.17	0.18	-0.16	0.84	0.78	-1.41	2.12
Cash from operations	23.8	62.9	35.8	-39.4	-30.3	-1.98	-17.9	26.8	66.2	74
Capital expenditures						-3.22	-1.51	-1.99
Acquisitions	-7.63	0	0				0	0	-7.86	-3.76
Cash from investing	-11.7	-5.4	-9.22	0.5	-4.56	-3.4	-2.66	-2.16	-9.58	-6.89
Stock issued	3.49	12	3.56	0.11	0.41	1.44	0.65	1	1.4	0
Share buybacks	-10.4	-68.3	-7.6	0	-0.9	0	0	-9.52	0	0
Cash from financing	-8.15	-60.4	-8.93	62.9	61.6	-3.35	-0.58	-8.57	-34.2	-5.41
Net change in cash	4.02	-2.85	17.6	24	26.7	-8.73	-21.1	16.1	22.4	61.7
Free cash flow						-5.2	-19.4	24.8
Interest paid	0.16	0.13	0.2	4.33	7.46	4.33	4.57	6.03	2.7	1.25
Income taxes paid	0.64	12.8	0.86	0.31	0.21	0.17	0.18	-0.55	3.25	8.51

Key metrics

Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $4.67 on September 25, 2026.

Profitability

Metric	Value	How it is calculated
Gross margin	78.8%	Gross profit / revenue.
Operating margin	2.5%	Operating income / revenue.
EBITDA margin	3.1%	EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin	3.2%	Pre-tax income / revenue.
Net margin	1.8%	Net income / revenue.
Operating cash flow margin	13.0%	Cash from operations / revenue.
Effective tax rate	45.9%	Income tax / pre-tax income, when pre-tax income is positive.
Return on equity (ROE)	2.9%	Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)	2.2%	Net income / average total assets.
Return on invested capital (ROIC)	4.9%	Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
R&D / revenue	4.3%	Research and development expense / revenue.
SG&A / revenue	71.8%	Selling, general and administrative expense / revenue.
Stock-based pay / revenue	1.9%	Stock-based compensation (from the cash flow statement) / revenue.
D&A / revenue	0.6%	Depreciation and amortization / revenue.

Growth

Metric	Value	How it is calculated
Revenue growth, 1y	20.0%	Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y	16.1%	Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y	11.0%	Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Gross profit growth, 1y	19.7%	Gross profit vs the same period a year earlier. Only from a positive base.
Gross profit CAGR, 3y	16.3%	Compound annual growth of gross profit over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Gross profit CAGR, 5y	10.6%	Compound annual growth of gross profit over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Operating income growth, 1y	8.5%	Operating income vs the same period a year earlier. Only from a positive base.
EBITDA growth, 1y	21.4%	EBITDA vs the same period a year earlier. Only from a positive base.
Net income growth, 1y	14.5%	Net income vs the same period a year earlier. Only from a positive base.
EPS growth, 1y	14.3%	EPS vs the same period a year earlier. Only from a positive base.
Operating cash flow growth, 1y	11.8%	Operating cash flow vs the same period a year earlier. Only from a positive base.
Book value growth, 1y	32.9%	Book value vs the same period a year earlier. Only from a positive base.
Total assets growth, 1y	29.8%	Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y	26.0%	Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y	11.1%	Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y	0.5%	Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y	9.9%	Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y	6.7%	Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.

Balance sheet health

Metric	Value	How it is calculated
Current ratio	5.33x	Current assets / current liabilities.
Quick ratio	4.60x	(Cash + short-term investments + receivables) / current liabilities.
Cash ratio	3.53x	(Cash + short-term investments) / current liabilities.
Debt / equity	0.08x	Total debt / shareholders' equity. Not shown when equity is negative.
Debt / assets	6.1%	Total debt / total assets.
Liabilities / assets	23.1%	Total liabilities / total assets.
Net debt	-$118.6M	Total debt - cash - short-term investments. Negative means more cash than debt.
Net debt / EBITDA	-10.9x	Net debt / EBITDA (twelve months), when EBITDA is positive.
Working capital	$166.9M	Current assets - current liabilities.
Goodwill and intangibles / assets	11.2%	(Goodwill + intangible assets) / total assets.
Tangible book value	$184.5M	Shareholders' equity - goodwill - intangible assets.

Efficiency

Metric	Value	How it is calculated
Asset turnover	1.26x	Revenue / average total assets.
Fixed asset turnover	72.3x	Revenue / average property, plant and equipment.
Inventory turnover	3.59x	Cost of revenue / average inventory.
Days inventory	102 days	365 x average inventory / cost of revenue.
Receivables turnover	8.60x	Revenue / average receivables.
Days sales outstanding	42 days	365 x average receivables / revenue.
Days payables	40 days	365 x average accounts payable / cost of revenue.
Cash conversion cycle	104 days	Days inventory + days sales outstanding - days payables.

Per share

Metric	Value	How it is calculated
EPS, diluted	$0.04	Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share	$2.40	Revenue / diluted weighted shares.
Operating cash flow per share	$0.31	Cash from operations / diluted weighted shares.
Book value per share	$1.48	Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Tangible book per share	$1.27	Tangible book value / shares outstanding.
Cash per share	$0.93	(Cash + short-term investments) / shares outstanding.

Valuation

Metric	Value	How it is calculated
Market cap	$680.7M	Share price x shares outstanding.
Enterprise value	$562.1M	Market cap + total debt - cash - short-term investments.
P/E	109x	Market cap / net income. Only when net income is positive.
P/S	1.92x	Market cap / revenue.
P/B	3.15x	Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book	3.69x	Market cap / tangible book value, when positive.
P/OCF	14.8x	Market cap / cash from operations, when positive.
EV/Sales	1.58x	Enterprise value / revenue.
EV/EBIT	64.2x	Enterprise value / operating income, when both are positive.
EV/EBITDA	51.7x	Enterprise value / EBITDA, when both are positive.
Earnings yield	0.9%	Net income / market cap (the inverse of P/E).

What was MIMEDX GROUP, INC.'s revenue in fiscal 2025?

MIMEDX GROUP, INC. reported revenue of $418.6M for fiscal 2025, 20% higher than the year before.

Was MIMEDX GROUP, INC. profitable in fiscal 2025?

Yes. Net income was $48.6M, a net margin of 11.6%.

Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.

Open interactive statements, quarterly figures and charts

Back to MIMEDX GROUP, INC.